Citation
81 FR 85982
Multiple canonical documents share this first-page citation.
- National Center for Advancing Translational Sciences; Notice of Meetings Tuesday, November 29, 2016 81 FR 85981
- National Center for Advancing Translational Sciences; Notice of Meetings Tuesday, November 29, 2016 81 FR 85981
- National Institute of Allergy and Infectious Diseases; Amended Notice of Meeting Tuesday, November 29, 2016 81 FR 85982
- National Institute of Allergy and Infectious Diseases; Amended Notice of Meeting Tuesday, November 29, 2016 81 FR 85982
- Prospective Grant of Exclusive Patent License: Development and Commercialization of Dopamine D3 Receptor Selective Antagonists/Partial Agonists for the Treatment of Opioid Use Disorder, Schizophrenia Bipolar Disorder and Tetrahydrocannabinol Dependence Tuesday, November 29, 2016 81 FR 85982
- Prospective Grant of Exclusive Patent License: Development and Commercialization of Dopamine D3 Receptor Selective Antagonists/Partial Agonists for the Treatment of Opioid Use Disorder, Schizophrenia Bipolar Disorder and Tetrahydrocannabinol Dependence Tuesday, November 29, 2016 81 FR 85982
- Federal Register Vol. 81, No.229, November 29, 2016 Tuesday, November 29, 2016 81 FR 85982